FDA accepts supplemental NDA for IQIRVO (elafibranor) by IPSEN
The FDA has accepted a supplemental NDA for IQIRVO (elafibranor) submitted by IPSEN, indicating a review process is underway.
Asset / Drug
Drug and asset intelligence for IPSEN with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.